Ziltivekimab, a proprietary anti-interleukin-6 ligand monoclonal antibody, targets residual inflammatory cardiovascular risk in advanced chronic kidney disease (CKD) patients. Developed as a therapy to reduce major cardiovascular adverse events in CKD patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients with moderate to severe CKD, ASCVD, and inflammation face high cardiovascular event risks with no approved prevention therapies available. Interleukin-6 (IL-6), a proinflammatory cytokine, is a known causal factor of ASCVD, supported by human genetic and preclinical studies. The drug is in Phase III development for treating moderate to severe CKD patients.
Read more from menafn.com
